Critical Path Institute (C-Path)

At the heart of Alzheimer’s disease research is the patient experience. C-Path emphasizes patient-centered research to ensure that treatments and trials align with what matters most to those living with the disease. By incorporating patient feedback into tools to support trial designs, C-Path aims to accelerate development of therapies that not only target the disease but improve quality of life. Patient voices are important as they shape the trajectory of Alzheimer’s disease research and help prioritize what needs the most attention. It’s vital to ensure that patients’ voices and their wellbeing aren’t forgotten in scientific progress. Learn more about how C-Path is driving these efforts by visiting c-path.org/cpad. #CPath #AlzheimersDiseaseAwarenessMonth #CPAD #Biomarkers #PatientVoice

🌍 World Prematurity Day | November 17, 2024 💜 Every year, over 13 million babies are born premature, many of them facing life-threatening challenges. This year’s motto, “Over 13 million babies born too soon every year. Access to quality care everywhere!”, calls for universal access to high-quality care for preterm babies, no matter where they are born. C-Path launched the International Neonatal Consortium in order to address a predictable regulatory path for advancing the safety and effectiveness of therapies for neonates across the world. This global public-private partnership is designed to create a regulatory pathway for evaluating the safety and efficacy of therapies for neonates. INC unites stakeholders from hospitals, research institutions, drug developers, patient advocacy groups, regulatory agencies, and other organizations around the world to generate consensus and develop tools that accelerate medical innovation for neonates. Let’s work together to ensure that every baby and their family receives the medical care and support they need. Join C-Path in raising awareness and advocating for better care for all preterm infants. Learn more about INC here: https://lnkd.in/gn28D6yk #CPath #WorldPrematurityDay2024 #WPD2024 #WorldPrematurityDay #WPD #BornTooSoon #PretermBirth

Biomarkers are accelerating drug development for Alzheimer’s disease. Critical Path for Alzheimer Disease is pioneering the way biomarkers are rigorously evaluated to ensure that they can be relied upon for use in clinical trial design. Biomarkers that are expected to predict clinical benefit based on appropriate studies, could change the entire landscape of Alzheimer’s treatment, including moving from reaction to prevention. Visit c-path.org/cpad to read more about the vital role of Biomarkers in Alzheimer’s disease. #CPath #AlzheimersDiseaseAwarenessMonth #CPAD #Biomarkers 

Day 2 of #CGIC2024 included an impactful session led by FDA's Michelle Campbell, and C-Path's Director of Advocacy, Thom Hart. The panel discussed: "Living Experiences in Action: Advocacy Update Across Rare Diseases."  Key Highlights from this session included: - Advocacy ensures future generations avoid past struggles.  - Involvement in advocacy organizations enhances patient representation.  - Incorporating those with lived experience in trial design is essential. - Collaboration among stakeholders can improve patient outcomes.  Watch the recording now: https://lnkd.in/ghErNryE #CPath #Advocacy #DrugDevelopment #RareDisease

Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/g9Weg2As For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience

REGISTRATION OPEN: eCOA Exchange #3 – Is there any point in eCOA libraries? eCOA libraries can be valuable assets in clinical research, offering ready-to-use, validated and pre-translated COA measures for collecting the trial participant’s voice. However, update varies hugely, and for a range of reasons. Do they really streamline the process and reduce costs? Join our expert panel as they identify and discuss the pros and cons of eCOA libraries, and whether we as an industry are deriving the true dividend that eCOA libraries claim to deliver.   Date: Wednesday, December 4, 2024 Time: 10:00-10:55 a.m. Eastern (US) Registration Open: https://lnkd.in/grYpbGZG eCOA members, include: ActiGraph Evinova Cambridge Cognition Clario ICON plc Inspired Health IQVIA Kayentis Koneksa Mapi Research Trust Medable, Inc Medidata Solutions Medrio ObvioHealth Parexel Red Nucleus RWS Group Signant Health Suvoda TransPerfect Life Sciences uMotif WCG YPrime   #CPath #eCOA #webinar #collaboration #drugdevelopment #datasharing #globalhealth #collaboration

In recognition of #WorldDiabetesDay, we're spotlighting C-Path’s Type 1 Diabetes Consortium and their groundbreaking work in T1D clinical trial innovation. A blog by C-Path's Scientific Director, Paul Belmonte, PhD, delves into the Consortium’s recent development of a regulatory-grade clinical trial simulation tool for new-onset type 1 diabetes. This tool, designed to support drug developers, leverages a robust model based on the C-peptide area under the curve measurement, promising to transform how new therapies are evaluated. Dive into Paul’s blog to learn how T1DC is paving the way for smarter, more effective trials in T1D treatment — just one of the many steps toward urgently needed therapies for the T1D community. 👉 Read the full blog here: https://lnkd.in/gBUjv329 Joseph Hedrick, Paul Belmonte, PhD #CPath #WorldDiabetesDay #DiabetesAwareness #ClinicalTrials #Type1Diabetes #CriticalPathInstitute #T1D #drugdevelopment #FDA #EMA #globalhealth #datasharing #collaboration

Did you know that you can now donate to C-Path using the Combined Federal Campaign? Are you a federal employee or retiree? Then GIVE HAPPY to us through the CFC using charity code #28364. One of the great benefits of the CFC is that you can give though payroll deduction or through your retiree annuity, giving a little each pay period and supporting our mission all year long. #CPath #CFC #Donate #DrugDevelopment 

Critical Path Institute® today announced a landmark initiative, Gender Equitable Medicines for Parkinson's Disease (GEM-PD), dedicated to globally advancing actionable research on how Parkinson’s disease uniquely impacts women and individuals across the sex and gender spectrum. “For nearly twenty years, C-Path has served as the worldwide leader in developing partnerships with a proven impact in accelerating drug development in neurological indications,” said C-Path CEO Klaus Romero, M.D., M.S., FCP. “GEM-PD will further catalyze our efforts to address unmet need in Parkinson’s disease therapies.” GEM-PD aims to accelerate the development of more personalized treatments by leveraging diverse data and innovative technologies, such as artificial intelligence and digital health technologies. The initiative seeks to generate drug development solutions that will lead to more equitable approaches to detection, disease management, and therapies for all individuals living with Parkinson’s. “As someone living with Parkinson’s, I’m hopeful that through a better understanding of how the disease affects women uniquely — from disease onset to clinical diagnosis and treatment response — we can develop treatments that truly reflect each person’s unique experience,” said Sarah Zenner-Dolan, Parkinson’s patient, and C-Path advisor. “This initiative gives me hope that future therapies will better address the specific challenges women face with Parkinson’s. It’s encouraging to see this focus on what matters most to us.” Full details, here: https://lnkd.in/grykkgfG Kristen Swingle Diane Stephenson Kimberly Ward Barowicz #CPath #Parkinsons #GEMPD #genderequitablemedicine #PD #drugdevelopment #personalizedmedicine #globalhealth #collaboration

Join us this week for "Advanced In Vitro Modeling of Neuromuscular Diseases and Therapeutics," Thursday, November 14, at Noon ET. This session will delve into the innovative multidisciplinary approaches being used to model diseases, test drugs, and engineer tissues in vitro. Dr. Francesco Saverio Tedesco, a renowned expert in neuromuscular research, will present developments, including the creation of advanced muscle models for the study of muscular dystrophies and the design of more targeted therapies. Attendees will gain valuable knowledge about the latest advancements in neuromuscular disease research and hear how collaborative, patient-centered efforts are accelerating progress in this field. ▶Register Now◀ to reserve your spot for this important discussion: https://lnkd.in/gpsX9bsW. Collin Hovinga Alexandre Bétourné, PhD, PharmD, PMP Laura Hopkins, MS, MLS Ramona Belfiore-Oshan Graham Marsh #CPath #RDCADAP #RareDisease #webinar #collaboration #neurmusculardisease #invitromodeling #globalhealth #drugdevelopment #datasharing